Martynoside

Martynoside protects ex vivo bone marrow cells from 5-fluorouracil (5-FU) -induced cell death and inflammation response by down-regulating the TNF signaling pathway[1].Martynoside is a potent antiestrogen in MCF-7 cells, increasing IGFBP3 levels

Product Specifications

CAS Number

[67884-12-2]

UNSPSC

12352005

Target

Others

Type

Natural Products

Related Pathways

Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer, Endocrinology

Assay Protocol

https://www.medchemexpress.com/martynoside.html

Purity

99.41

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

COC(C=C1/C=C/C(O[C@H]([C@H](O[C@H]([C@@H]2O)OCCC3=CC(O)=C(C=C3)OC)CO)[C@@H]2O[C@H]4[C@@H]([C@@H]([C@H]([C@@H](O4)C)O)O)O)=O)=C(C=C1)O

Molecular Formula

C31H40O15

Molecular Weight

652.64

References & Citations

[1]Hong M, et al. Ex vivo and in vivo chemoprotective activity and potential mechanism of Martynoside against 5-fluorouracil-induced bone marrow cytotoxicity. Biomed Pharmacother. 2021;138:111501.|[2]Papoutsi Z, et al. Acteoside and martynoside exhibit estrogenic/antiestrogenic properties. J Steroid Biochem Mol Biol. 2006;98 (1) :63-71.